Back to Search
Start Over
COVID-19 Vaccine: A comprehensive status report
- Source :
- Virus Research
- Publication Year :
- 2020
- Publisher :
- Elsevier BV, 2020.
-
Abstract
- Highlights • Platforms for COVID-19 vaccine development. • Clinical Trials in COVID-19 and their results. • Use of preformed antibodies. • Vaccine development and its limitations.<br />The current COVID-19 pandemic has urged the scientific community internationally to find answers in terms of therapeutics and vaccines to control SARS-CoV-2. Published investigation mostly on SARS-CoV and to extent on MERS has taught lessons to vaccination strategies to this novel coronavirus. This is attributed to the fact that SARS-CoV-2 uses the same receptor as SARS-CoV on host cell i.e. human Angiotensin Converting Enzyme 2 (hACE2) and is approximately 79% similar genetically to SARS-CoV. Though the efforts on COVID-19 vaccines started very early, initially in China, as soon as the outbreak of novel coronavirus erupted and then world-over as the disease was declared a pandemic by WHO. But we will not be having an effective COVID-19 vaccine before September, 2020 as per very optimistic estimates. This is because a successful COVID-19 vaccine will require a cautious validation of efficacy and adverse reactivity as the target vaccinee population include high-risk individuals over the age of 60, particularly those with chronic co-morbid conditions, frontline healthcare workers and those involved in essentials industries. Various platforms for vaccine development are available namely: virus vectored vaccines, protein subunit vaccines, genetic vaccines, and monoclonal antibodies for passive immunization which are under evaluations for SARS-CoV-2, with each having discrete benefits and hindrances. The COVID-19 pandemic which probably is the most devastating one in the last 100 years after Spanish flu mandates the speedy evaluation of the multiple approaches for competence to elicit protective immunity and safety to curtail unwanted immune-potentiation which plays an important role in the pathogenesis of this virus. This review is aimed at providing an overview of the efforts dedicated to an effective vaccine for this novel coronavirus which has crippled the world in terms of economy, human health and life.
- Subjects :
- Cancer Research
DC, Dendritic Cells
Convalescent Plasma Therapy
Disease
Antibodies, Viral
medicine.disease_cause
nAb, Neutralizing Antibody
DPP4, Dipeptidyl Peptidase
MERS-CoV, Middle East Respiratory Syndrome Coronavirus
Immunogenicity, Vaccine
SARS, Severe Acute Respiratory Syndrome
Health care
Pandemic
Vaccines, DNA
CoV, Coronavirus
Coronavirus
Clinical Trials as Topic
0303 health sciences
education.field_of_study
TMPRSS2, Transmembrane Protease Serine 2
Viral Vaccine
ARDS, Acute Respiratory Distress Syndrome
Vaccination
ADE, Antibody-Dependent Enhancement
Infectious Diseases
COVID-19, Coronavirus Disease 2019
Vaccines, Subunit
Receptors, Virus
TLR, Toll-Like Receptor
Angiotensin-Converting Enzyme 2
Patient Safety
RBD, Receptor Binding Domains
Coronavirus Infections
medicine.medical_specialty
COVID-19 Vaccines
NTD, N Terminal Domain
Genetic Vectors
Pneumonia, Viral
Population
Peptidyl-Dipeptidase A
Biology
NSP, Non-structural Proteins
Vaccines, Attenuated
Article
Betacoronavirus
03 medical and health sciences
Patient safety
Virology
RBM, Receptor Binding Motif
medicine
Humans
Clinical Trials
CP, Convalescent Plasma
Vaccines, Virus-Like Particle
SARS-CoV, Severe Acute Respiratory Syndrome Coronavirus
Intensive care medicine
education
Pandemics
COVID-19 Serotherapy
030304 developmental biology
VLP, Virus-Like Particle
SARS-CoV-2
030306 microbiology
business.industry
Immunization, Passive
COVID-19
LAV, Live Attenuated Vaccine
Viral Vaccines
Immunity, Innate
Monoclonal Antibodies
LNP, Lipid Nanoparticle
SARS-CoV-2, Severe Acute Respiratory Syndrome Coronavirus 2
business
Vaccine
hACE2, Human Angiotensin- Converting Enzyme 2
Subjects
Details
- ISSN :
- 01681702
- Volume :
- 288
- Database :
- OpenAIRE
- Journal :
- Virus Research
- Accession number :
- edsair.doi.dedup.....fb8b20b28fee5cd41b0256ac733419d9
- Full Text :
- https://doi.org/10.1016/j.virusres.2020.198114